Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.72 |
| ▸ | PPARA | Q07869 | 4/20 | 0.59 |
| ▸ | CTSK | P43235 | 7/20 | 0.56 |
| ▸ | CTSS | P25774 | 8/20 | 0.55 |
| ▸ | CTSL | P07711 | 5/20 | 0.55 |
| ▸ | CTSB | P07858 | 4/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890758 | 1.00 | SYK (0.72) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL615358 | 1.00 | SYK (0.72) | SYKPPARACTSKCTSSCTSL | |
| Hydrochloric Acid SCHEMBL7376426 | 0.99 | SYK (0.71) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL17841824 | 0.95 | SYK (0.65) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL606625 | 0.95 | SYK (0.65) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL1022494 | 0.95 | SYK (0.65) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL30460045 | 0.93 | SYK (0.72) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL3897638 | 0.93 | SYK (0.72) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL28884211 | 0.92 | SYK (0.62) | SYKPPARACTSKCTSSCTSL | |
| SCHEMBL27450774 | 0.92 | SYK (0.62) | SYKPPARACTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605458-B2 | Antibody-drug conjugate having acidic self-stabilization junction | SYSTIMMUNE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20240409556-A1 | BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024213625-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112513036-B | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | 福马治疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-6034238-A | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENT | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-03-07 | — | — | US | disclosed |
| US-5998447-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT AG (DE) | 1999-12-07 | — | — | US | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| US-4521432-A | ANTIDIABEWTIC, REAGENT FOR STUDYING FATTY ACID METABOLISM | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-06-04 | — | — | US | disclosed |
| EP-0080695-B1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE FA-5859, ITS DERIVATIVE; THEIR PRODUCTION AND ANTIDIABETIC AGENTS CONTAINING SAID COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | SYK 611/4885PPARA 4860/4885CTSK 85/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SYK 2751/4885PPARA 2034/4885CTSK 774/4885 |
| US-20240409556-A1 | BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD3 | SYK 3785/4885PPARA 193/4885CTSK 3772/4885 |
| US-12605458-B2 | Antibody-drug conjugate having acidic self-stabilization junction | PAICS, CA13, CA6 | SYK 1564/4885PPARA 4378/4885CTSK 3883/4885 |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | SYK 4705/4885PPARA 3205/4885CTSK 1529/4885 |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | ABCB11, ABCB1, ABCG2 | SYK 2944/4885PPARA 2975/4885CTSK 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.